11:05 AM EDT, 08/08/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) investors can move ahead with claims that certain company directors and executives breached securities laws and fiduciary duties regarding its infant formula safety, while the remaining claims were dismissed, a federal court ruled Wednesday.

At issue is the company's plant in Sturgis, Michigan, that was closed in 2022 after the US Food and Drug Administration found deadly bacteria in its Similac powdered infant formula, prompting Abbott to recall the product.

Judge Sunil Harjani of the US District Court for the Northern District of Illinois on Wednesday ruled that the defendants' motion to dismiss the case was granted in part and denied in part, with only two of the seven counts surviving.

The defendants' answer to the surviving counts is due by Sept. 11, according to the court filing.

Abbott didn't immediately respond to MT Newswires' request for comment.

Price: 109.90, Change: -0.04, Percent Change: -0.04